Mehmet Cem Fidan

6PUBLICATIONS
39CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 09, 2026
Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group.

|Aug 27, 2026
Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort.

|Aug 13, 2026
Does the CRP/Albumin Ratio Independently Predict Survival in Metastatic Colorectal Cancer? Insights from a Propensity Score-Matched Cohort.

|May 06, 2026
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).

|Sep 27, 2025
Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer.

Murat Günaltılı, Murad Guliyev, Mehmet Cem Fidan

|Jul 12, 2025
First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.

Mehmet Cem Fidan, Ahmet Emin Öztürk, Okan Aydın

Pageof 1

Frequent Collaborators

5 joint publications

Murad Guliyev

5 joint publications

Özkan Alan

3 joint publications

Emir Cerme

2 joint publications

Seda Jeral